Clearside picks up $7.9M for microneedle blindness treatment; Ampio embarks on clinical trials for oral diabetic treatment;

@MichaelGFierce: Sanofi's Genzyme hits target with muscular dystrophy RNA drug in mice. Article | Follow @MichaelGFierce

> Clearside Biomedical has raised $7.9 million to finance a microneedle to deliver drugs to the back of the eye for the treatment of retinal blindness, and the startup could raise as much as $8.5 million more before beginning clinical testing in the first quarter of this year, if all goes as planned. Story

> Ampio Pharmaceuticals ($AMPE) began a clinical trial of Optina, its oral version of a drug to treat diabetic macular edema--previous treatments all required an injection directly into the eye. Release

> Intersect ENT received $30 million in Series D funding for its quarter-sized implants to treat chronic sinusitis. The device releases a steroid drug to keep the sinus open and attracted attention from Medtronic ($MDT). Story

> Cumberland Pharmaceuticals and Sandor Medicaids signed a commercialization agreement for an injectable ibuprofen drug in India, marking the first time in the country that the drug is available in such a form. Release

> Results from a Phase III study showed that once-daily, inhaled tiotropium from Boehringer Ingelheim improved lung function in asthma patients who have allergies that affect their reactions to other treatments. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.